Oculis schedules Licaminlimab presentation ahead of trial results

• Oculis (NASDAQ:OCS) scheduled an October 8 presentation at Eyecelerator @ AAO 2026 to outline its investigational topical treatment, Licaminlimab.
• The presentation will immediately precede the company's sponsored Neuro-Ophthalmology Subspecialty Day on October 9 in New Orleans.
• The company expects the presentation to provide clinical context ahead of the PREDICT-1 registrational symptoms trial, which is forecast to deliver topline results near year-end.

Oculis (NASDAQ:OCS) will present its investigational dry eye treatment, Licaminlimab, at the Eyecelerator @ AAO 2026 conference on October 8.

The upcoming presentation will highlight a genotype-based clinical approach for TNFR1-mediated dry eye disease ahead of late-stage data readouts.

Chief Executive Officer Riad Sherif is scheduled to lead the Anterior segment showcase presentation to detail the therapeutic mechanics of the asset.

The company stated that it expects the PREDICT-1 registrational symptoms trial, which was designed to support commercial registration, to deliver topline results around year-end.

To support its medical outreach, the company will also sponsor the Neuro-Ophthalmology Subspecialty Day on October 9 at the American Academy of Ophthalmology Annual Meeting in New Orleans.

The scheduled clinical updates reflect the operational strategy to outline developmental progress in the broader anterior segment and neuro-ophthalmology markets.